企業プロフィール
Intensity Therapeutics 株価・ニュース・カタリスト
- ティッカー:
- INTS
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
4.15 USD (+4.80%)
終値
最終更新: 2026年8月17日
11.6M USD
時価総額
株価変動の要因
As of Aug 17, 2026, INTS closed up 4.80% at $4.15. No new same-company headline was identified in the current news window.
企業概要
Intratumoral Cancer Therapy
Intensity Therapeutics develops medicines administered directly into tumors. Its approach is designed to kill injected tumor cells, expose tumor antigens, and stimulate a broader immune response.
INT230-6
INT230-6 combines cytotoxic agents with a proprietary dispersion molecule intended to improve penetration throughout solid tumors. The candidate is being studied both before surgery and in advanced disease.
Soft-Tissue Sarcoma
The Phase 3 INVINCIBLE-3 study evaluates INT230-6 as second- or third-line monotherapy against standard of care in soft-tissue sarcoma, with overall survival as the primary outcome.
Triple-Negative Breast Cancer
The Phase 2 INVINCIBLE-4 study evaluates presurgical INT230-6 followed by standard immunochemotherapy against standard treatment alone in triple-negative breast cancer.
今後のカタリスト
- Resumption of patient enrollment at a limited number of U.S. sites in the Phase 3 INVINCIBLE-3 study by the third quarter of 2026.
- Completion of enrollment in the Phase 2 INVINCIBLE-4 study by the end of 2027.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。